Isolated central nervous system progression on Crizotinib

References

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212 - 36; http://dx.doi.org/10.3322/caac.20121; PMID: 21685461
   PubMed Web of Science ®Google Scholar
• Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007; 25:561 - 70; http://dx.doi.org/10.1200/JCO.2006.06.8015; PMID: 17290066
   PubMed Web of Science ®Google Scholar
• Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. Nat Rev Clin Oncol 2010; 7:401 - 14; http://dx.doi.org/10.1038/nrclinonc.2010.64; PMID: 20551945
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011; 9:1335 - 41; PMID: 22157554
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561 - 6; http://dx.doi.org/10.1038/nature05945; PMID: 17625570
   PubMed Web of Science ®Google Scholar
• Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174:661 - 70; http://dx.doi.org/10.2353/ajpath.2009.080755; PMID: 19147828
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011; 17:2081 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-10-1591; PMID: 21288922
   PubMed Web of Science ®Google Scholar
• Mossé YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009; 15:5609 - 14; http://dx.doi.org/10.1158/1078-0432.CCR-08-2762; PMID: 19737948
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12:1004 - 12; http://dx.doi.org/10.1016/S1470-2045(11)70232-7; PMID: 21933749
   PubMed Web of Science ®Google Scholar
• Yang T, Liu H, Chen J. [EML4-ALK fusion gene in lung cancer and its biological function]. Zhongguo Fei Ai Za Zhi 2012; 15:112 - 6; PMID: 22336240
   PubMedGoogle Scholar
• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693 - 703; http://dx.doi.org/10.1056/NEJMoa1006448; PMID: 20979469
   PubMed Web of Science ®Google Scholar
• Kim YH, Mishima M. Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treat Rev 2011; 37:505 - 10; http://dx.doi.org/10.1016/j.ctrv.2010.12.007; PMID: 21257270
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92 - 8; http://dx.doi.org/10.1056/NEJMoa011954; PMID: 11784875
   PubMed Web of Science ®Google Scholar
• Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011; 54:6342 - 63; http://dx.doi.org/10.1021/jm2007613; PMID: 21812414
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 2012; 340:549 - 57; http://dx.doi.org/10.1124/jpet.111.188870; PMID: 22129595
   PubMed Web of Science ®Google Scholar
• Joshi M, Jiang Y, Belani CP. Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. Expert Opin Pharmacother 2012; 13:685 - 97; http://dx.doi.org/10.1517/14656566.2012.668530; PMID: 22404744
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29:e443 - 5; http://dx.doi.org/10.1200/JCO.2010.34.1313; PMID: 21422405
   PubMed Web of Science ®Google Scholar
• Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012; 72:100 - 11; http://dx.doi.org/10.1158/0008-5472.CAN-11-1403; PMID: 22080568
   PubMed Web of Science ®Google Scholar
• Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008; 105:19893 - 7; http://dx.doi.org/10.1073/pnas.0805381105; PMID: 19064915
   PubMed Web of Science ®Google Scholar
• Li Y, Ye X, Liu J, Zha J, Pei L. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011; 13:1 - 11; PMID: 21245935
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14:4275 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-08-0168; PMID: 18594010
   PubMed Web of Science ®Google Scholar
• Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420:345 - 61; http://dx.doi.org/10.1042/BJ20090387; PMID: 19459784
   PubMed Web of Science ®Google Scholar
• Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004; 199:330 - 58; http://dx.doi.org/10.1002/jcp.10472; PMID: 15095281
   PubMed Web of Science ®Google Scholar
• Perez-Pinera P, Chang Y, Deuel TF. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle 2007; 6:2877 - 83; http://dx.doi.org/10.4161/cc.6.23.5090; PMID: 18156802
   PubMed Web of Science ®Google Scholar
• Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 2008; 33:685 - 700; http://dx.doi.org/10.1038/sj.npp.1301446; PMID: 17487225
   PubMed Web of Science ®Google Scholar
• Galetta D, Rossi A, Pisconti S, Colucci G. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets 2012; 16:Suppl 2 S45 - 54; http://dx.doi.org/10.1517/14728222.2011.642372; PMID: 22443113
   PubMed Web of Science ®Google Scholar
• Gandhi L, Jänne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012; 18:3737 - 42; http://dx.doi.org/10.1158/1078-0432.CCR-11-2393; PMID: 22547770
   PubMed Web of Science ®Google Scholar
• Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45:427 - 34; http://dx.doi.org/10.1016/S0360-3016(99)00198-4; PMID: 10487566
   PubMed Web of Science ®Google Scholar
• Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134 - 41; http://dx.doi.org/10.1200/JCO.2010.30.1655; PMID: 21041710
   PubMed Web of Science ®Google Scholar
• Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012; 26; PMID: 22260435
   PubMed Web of Science ®Google Scholar
• Han C, Ma J, Zhao J, Zhou Y, Jing W, Zou H. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis. Cancer Invest 2011; 29:626 - 34; http://dx.doi.org/10.3109/07357907.2011.621914; PMID: 22011285
   PubMed Web of Science ®Google Scholar
• Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012; 118:729 - 39; http://dx.doi.org/10.1002/cncr.26311; PMID: 21720997
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al, ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734 - 9; http://dx.doi.org/10.1056/NEJMoa1007478; PMID: 20979473
   PubMed Web of Science ®Google Scholar
• Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL, Wilner KD, et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012; 30:e30 - 3; http://dx.doi.org/10.1200/JCO.2011.38.4586; PMID: 22162573
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Y, Chen Y, Sun S, Li N, Lv D, et al. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer 2007; 57:37 - 45; http://dx.doi.org/10.1016/j.lungcan.2007.02.020; PMID: 17418446
   PubMed Web of Science ®Google Scholar
• Gore E. RTOG 0214: a phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol 2005; 3:625 - 6; PMID: 16167048
   PubMedGoogle Scholar
• Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al, EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357:664 - 72; http://dx.doi.org/10.1056/NEJMoa071780; PMID: 17699816
   PubMed Web of Science ®Google Scholar
• Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al, Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341:476 - 84; http://dx.doi.org/10.1056/NEJM199908123410703; PMID: 10441603
   PubMed Web of Science ®Google Scholar
• Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009; 65:198 - 203; http://dx.doi.org/10.1016/j.lungcan.2008.10.028; PMID: 19091441
   PubMed Web of Science ®Google Scholar
• Kawabe T, Phi JH, Yamamoto M, Kim DG, Barfod BE, Urakawa Y. Treatment of brain metastasis from lung cancer. Prog Neurol Surg 2012; 25:148 - 55; http://dx.doi.org/10.1159/000331188; PMID: 22236676
   PubMedGoogle Scholar
• Kim A, McCully C, Cruz R, Cole DE, Fox E, Balis FM, et al. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs 2012; 30:524 - 8; http://dx.doi.org/10.1007/s10637-010-9585-1; PMID: 21072558
   PubMed Web of Science ®Google Scholar